Clinical trials: Microtia
Microtia
Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201
Long-term follow-up of unilateral microtia patients implanted with AUR-201.
- Trial name
- AUR-201 (NCT06078566)
- Testing
- AUR-201
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Auregen Biotherapeutics, SA
Microtia
AuriNovo for Auricular Reconstruction
AuriNovo provides a patient-specific, biological construct for use in the surgical reconstruction of the external ear in people born with microtia Grades II-IV.
- Trial name
- NCT04399239
- Testing
- AuriNovo
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- 3DBio Therapeutics
Microtia
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.
- Trial name
- AUR-201 (NCT06072040)
- Testing
- AUR-201
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Auregen Biotherapeutics, SA
Ear Deformities, Acquired, Ear; Deformity, Congenital
Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures
This study evaluates the efficacy of the AuryzoN devices in the ear and nose reconstruction surgeries, both in terms of operative time and overall quality of reconstruction.
- Conditions
- Ear Deformities, Acquired, Ear; Deformity, Congenital, Microtia, Nose Deformity
- Trial name
- NCT03624608
- Testing
- AuryzoN Family of Devices
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Reconstrata, LLC
Microtia
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.
- Trial name
- AUR-201 (NCT06225336)
- Testing
- AUR-201
- Where
- Australia
- Volunteers
- 2 people
- Sponsor
- Auregen Biotherapeutics, SA